top of page


Menarini Stemline licenses Georgiamune GIM-621 oral cancer immunotherapy in deal worth up to $1.1 billion
Menarini's Stemline Therapeutics has secured worldwide rights to Georgiamune's investigational oral cancer immunotherapy GIM-621 in a licensing agreement worth up to $1.1 billion.

nuaxia
Oct 232 min read


European Commission approves Ubeslo and Evlarco for high LDL cholesterol
The European Commission has approved Ubeslo and Evlarco for treatment of primary hypercholesterolaemia or mixed dyslipidaemia, marking the first regulatory approval worldwide for obicetrapib.

nuaxia
Sep 231 min read
bottom of page